Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021 Jul 6, 2021 08:30AM
Novavax (NVAX) Publishes Results of United Kingdom Phase 3 Clinical Trial in NEJM, Demonstrating High Levels of Efficacy of COVID-19 Vaccine Jun 30, 2021 05:27PM
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine Jun 30, 2021 05:26PM
Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum Jun 17, 2021 04:02PM
Novavax to Participate in National Vaccine Advisory Committee Meeting Jun 17, 2021 09:22AM
View Older Stories

Jun 14, 2021 04:05PM Novavax (NVAX) Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
Jun 14, 2021 04:05PM Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
Jun 14, 2021 06:10AM Novavax (NVAX) COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Jun 14, 2021 06:00AM Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Jun 11, 2021 04:07PM Novavax (NVAX) Announces Positive Data from Three Studies of its Vaccine Against South African Strain
Jun 11, 2021 04:05PM Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
Jun 9, 2021 09:03AM Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters
Jun 7, 2021 04:05PM Novavax to Participate in Panel at BIO Digital 2021
May 27, 2021 08:30AM Novavax to Participate in Jefferies Virtual Healthcare Conference
May 24, 2021 05:03PM Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update
May 22, 2021 12:20PM Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea
May 21, 2021 08:53AM Novavax Honored by Maryland Tech Council During 2021 Industry Awards Celebration
May 10, 2021 04:02PM Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
May 10, 2021 09:13AM Novavax (NVAX) Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
May 10, 2021 09:12AM Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
May 6, 2021 09:07AM Novavax (NVAX) and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
May 6, 2021 09:05AM Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
May 5, 2021 05:07PM Novavax (NVAX) Announces NEJM Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant
May 5, 2021 05:03PM New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant
May 3, 2021 08:52AM Novavax (NVAX) Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
May 3, 2021 08:51AM Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
Apr 23, 2021 04:02PM Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021
Apr 23, 2021 05:54AM Novavax (NVAX) Reports Publication of Data from Phase 2b Clinical Trial for Malaria Vaccine Candidate, R21, in Children Demonstrating 77% Efficacy
Apr 23, 2021 05:00AM Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
Apr 14, 2021 05:40PM Novavax (NVAX) to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
Apr 14, 2021 05:39PM Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
Apr 13, 2021 05:36PM Novavax (NVAX) announces Gale E. Smith, Ph.D. promoted to Senior Vice President, Greg Covino to step down as CFO
Apr 13, 2021 05:34PM Novavax Announces Leadership Updates
Apr 5, 2021 04:06PM Novavax (NVAX) Initiates COVID-19 Vaccine Clinical Trial Crossover
Apr 5, 2021 04:05PM Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
Apr 5, 2021 08:50AM Novavax CEO Stan Erck to Participate in Longwood Healthcare Leaders Meeting
Mar 29, 2021 04:03PM GSK (GSK) to support manufacture of Novavax' (NVAX) COVID-19 vaccine
Mar 29, 2021 04:02PM GSK to support manufacture of Novavax' COVID-19 vaccine
Mar 11, 2021 04:02PM Novavax (NVAX) COVID-19 Vaccine Shows High Levels of Efficacy Against Original and Variant COVID-19 Strains
Mar 11, 2021 04:02PM Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
Mar 8, 2021 06:00PM Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat
Mar 1, 2021 04:02PM Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Feb 26, 2021 08:25AM Novavax (NVAX), Takeda (TAK) Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Feb 26, 2021 08:22AM Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Feb 26, 2021 08:22AM Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Feb 22, 2021 07:13AM Novavax (NVAX) Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Feb 22, 2021 07:00AM Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Feb 22, 2021 07:00AM Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Feb 18, 2021 04:04PM Novavax (NVAX) Enters MOU with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
Feb 18, 2021 04:02PM Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
Feb 18, 2021 04:02PM Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
Feb 16, 2021 08:00AM Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021
Feb 15, 2021 08:04PM Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
Feb 15, 2021 08:04PM Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
Feb 4, 2021 04:58PM Novavax (NVAX) Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
View Older Stories